SI3160948T1 - Amidi benzoksazinona, kot modulatorji receptorja mineralokortikoida - Google Patents
Amidi benzoksazinona, kot modulatorji receptorja mineralokortikoidaInfo
- Publication number
- SI3160948T1 SI3160948T1 SI201530572T SI201530572T SI3160948T1 SI 3160948 T1 SI3160948 T1 SI 3160948T1 SI 201530572 T SI201530572 T SI 201530572T SI 201530572 T SI201530572 T SI 201530572T SI 3160948 T1 SI3160948 T1 SI 3160948T1
- Authority
- SI
- Slovenia
- Prior art keywords
- modulators
- mineralocorticoid receptor
- benzoxazinone
- amides
- benzoxazinone amides
- Prior art date
Links
- -1 Benzoxazinone amides Chemical class 0.000 title 1
- 102000003979 Mineralocorticoid Receptors Human genes 0.000 title 1
- 108090000375 Mineralocorticoid Receptors Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
- C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462018790P | 2014-06-30 | 2014-06-30 | |
| EP15736015.7A EP3160948B1 (en) | 2014-06-30 | 2015-06-26 | Benzoxazinone amides as mineralocorticoid receptor modulators |
| PCT/GB2015/051860 WO2016001631A1 (en) | 2014-06-30 | 2015-06-26 | Benzoxazinone amides as mineralocorticoid receptor modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI3160948T1 true SI3160948T1 (sl) | 2020-06-30 |
Family
ID=53539739
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201530572T SI3160948T1 (sl) | 2014-06-30 | 2015-06-26 | Amidi benzoksazinona, kot modulatorji receptorja mineralokortikoida |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US10017502B2 (https=) |
| EP (1) | EP3160948B1 (https=) |
| JP (1) | JP6368383B2 (https=) |
| KR (1) | KR102012222B1 (https=) |
| CN (1) | CN106536491B (https=) |
| AR (1) | AR101036A1 (https=) |
| AU (1) | AU2015282450C1 (https=) |
| CA (1) | CA2953655C (https=) |
| CY (1) | CY1121596T1 (https=) |
| DK (1) | DK3160948T3 (https=) |
| EA (1) | EA029518B1 (https=) |
| ES (1) | ES2707726T3 (https=) |
| HR (1) | HRP20190147T1 (https=) |
| HU (1) | HUE042370T2 (https=) |
| LT (1) | LT3160948T (https=) |
| ME (1) | ME03316B (https=) |
| MX (1) | MX367404B (https=) |
| PL (1) | PL3160948T3 (https=) |
| PT (1) | PT3160948T (https=) |
| RS (1) | RS58274B1 (https=) |
| SI (1) | SI3160948T1 (https=) |
| SM (1) | SMT201900039T1 (https=) |
| TR (1) | TR201900659T4 (https=) |
| TW (1) | TWI677498B (https=) |
| UY (1) | UY36195A (https=) |
| WO (1) | WO2016001631A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3160948B1 (en) * | 2014-06-30 | 2018-10-24 | Astrazeneca AB | Benzoxazinone amides as mineralocorticoid receptor modulators |
| MA53175A (fr) | 2018-07-19 | 2021-05-26 | Astrazeneca Ab | Méthodes de traitement de hfpef au moyen de dapagliflozine et compositions comprenant celle-ci |
| CN112107568B (zh) * | 2019-06-19 | 2022-03-25 | 北京龙嘉博创医药科技有限公司 | 二芳基酰胺类化合物及其应用 |
| PE20211267A1 (es) | 2019-08-30 | 2021-07-19 | Astrazeneca Ab | Metodos de tratamiento de la insuficiencia cardiaca con fraccion de eyeccion reducida con dapagliflozina |
| CN116392472B (zh) | 2020-07-27 | 2025-06-20 | 阿斯利康(瑞典)有限公司 | 用达格列净治疗慢性肾脏病的方法 |
| US12409186B2 (en) | 2020-07-27 | 2025-09-09 | Astrazeneca Ab | Methods of treating chronic kidney disease with dapagliflozin |
| MX2023015144A (es) | 2021-06-15 | 2024-01-22 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | Derivados de benzoxazinona. |
| TW202409023A (zh) | 2022-07-14 | 2024-03-01 | 美商富曼西公司 | 除草苯并𠯤 |
| AU2023331475A1 (en) | 2022-09-01 | 2025-04-17 | Astrazeneca Ab | Combination of sglt2 inhibitors and mineralcorticoid receptor modulators for use in treatment of cardiorenal diseases |
| WO2024125591A1 (zh) * | 2022-12-15 | 2024-06-20 | 正大天晴药业集团股份有限公司 | 苯并恶嗪酮类化合物的结晶及其制备 |
| WO2025111184A1 (en) | 2023-11-21 | 2025-05-30 | Fmc Corporation | Substituted tetrahydroquinoline and tetrahydroquinoxaline herbicides |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6951855B2 (en) * | 2001-04-23 | 2005-10-04 | Astrazeneca Ab | Benzoxazinone derivatives for use in the treatment of angiogenesis |
| CA2510851A1 (en) * | 2002-12-20 | 2004-07-08 | Warner-Lambert Company Llc | Benzoxazines and derivatives thereof as inhibitors of pi3ks |
| CN101018552A (zh) * | 2004-07-14 | 2007-08-15 | 利亘制药公司 | 细胞内受体调节剂化合物和方法 |
| US20090054417A1 (en) * | 2004-07-28 | 2009-02-26 | Irm Llc | Compounds and compositions as modulators of steroid hormone nuclear receptors |
| CA2635541A1 (en) | 2005-12-28 | 2007-07-12 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compounds and their use as mineralocorticoid receptor ligands |
| TWI385161B (zh) | 2006-02-02 | 2013-02-11 | Mitsubishi Tanabe Pharma Corp | 含氮雜雙環化合物 |
| DK2089367T3 (da) | 2006-10-31 | 2012-02-06 | Pfizer Prod Inc | Pyrazolinforbindelser som mineralocorticoidreceptor-antagonister |
| DE102007009494A1 (de) | 2007-02-27 | 2008-08-28 | Bayer Healthcare Ag | Substituierte 4-Aryl-1, 4-dihydro-1,6-naphthyridinamide und ihre Verwendung |
| EP2139489A4 (en) | 2007-03-23 | 2011-11-02 | Merck Sharp & Dohme | Mineralocorticoid receptor modulators |
| EP2133330B1 (en) | 2007-04-09 | 2014-01-01 | Daiichi Sankyo Company, Limited | Atropisomer of pyrrole derivative |
| JP5173653B2 (ja) * | 2007-08-01 | 2013-04-03 | 田辺三菱製薬株式会社 | 医薬組成物 |
| US8258131B2 (en) | 2007-08-01 | 2012-09-04 | Mitsubishi Tanabe Pharma Corporation | Fused bicyclic compound |
| TWI431010B (zh) | 2007-12-19 | 2014-03-21 | Lilly Co Eli | 礦皮質素受體拮抗劑及使用方法 |
| UY31905A (es) * | 2008-06-18 | 2010-01-29 | Astrazeneca Ab | Derivados de benzoxazinona, procesos de preparación, composiciones farmacéuticas conteniéndolos y aplicaciones. |
| US20100094000A1 (en) | 2008-09-03 | 2010-04-15 | Takeda Pharmaceutical Company Limited | Pyrazole compounds |
| WO2010098286A1 (ja) | 2009-02-25 | 2010-09-02 | 第一三共株式会社 | ミネラルコルチコイド受容体拮抗薬を含有する医薬 |
| WO2010104721A1 (en) | 2009-03-12 | 2010-09-16 | Eli Lilly And Company | Mineralocorticoid receptor antagonist and methods of use |
| JP2012523405A (ja) | 2009-04-10 | 2012-10-04 | ファイザー・インク | ４，５−ジヒドロ−１ｈ−ピラゾール化合物およびその薬学的使用 |
| WO2011141848A1 (en) | 2010-05-11 | 2011-11-17 | Pfizer Inc. | Morpholine compounds as mineralocorticoid receptor antagonists |
| WO2011141846A2 (en) | 2010-05-11 | 2011-11-17 | Koninklijke Philips Electronics N.V. | Lighting module |
| US20130116227A1 (en) | 2010-07-13 | 2013-05-09 | Dainippon Sumitomo Pharma Co., Ltd. | Biaryl amide derivative or pharmaceutically acceptable salt thereof |
| JP2013542255A (ja) | 2010-11-10 | 2013-11-21 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ミネラルコルチコイド受容体アンタゴニストとしてのピリジル尿素 |
| EP3160948B1 (en) * | 2014-06-30 | 2018-10-24 | Astrazeneca AB | Benzoxazinone amides as mineralocorticoid receptor modulators |
-
2015
- 2015-06-26 EP EP15736015.7A patent/EP3160948B1/en active Active
- 2015-06-26 KR KR1020177002518A patent/KR102012222B1/ko active Active
- 2015-06-26 LT LTEP15736015.7T patent/LT3160948T/lt unknown
- 2015-06-26 CA CA2953655A patent/CA2953655C/en active Active
- 2015-06-26 JP JP2016575499A patent/JP6368383B2/ja active Active
- 2015-06-26 MX MX2017000183A patent/MX367404B/es active IP Right Grant
- 2015-06-26 SI SI201530572T patent/SI3160948T1/sl unknown
- 2015-06-26 SM SM20190039T patent/SMT201900039T1/it unknown
- 2015-06-26 WO PCT/GB2015/051860 patent/WO2016001631A1/en not_active Ceased
- 2015-06-26 ES ES15736015T patent/ES2707726T3/es active Active
- 2015-06-26 PL PL15736015T patent/PL3160948T3/pl unknown
- 2015-06-26 HU HUE15736015A patent/HUE042370T2/hu unknown
- 2015-06-26 US US15/320,379 patent/US10017502B2/en active Active
- 2015-06-26 CN CN201580035032.8A patent/CN106536491B/zh active Active
- 2015-06-26 EA EA201790046A patent/EA029518B1/ru not_active IP Right Cessation
- 2015-06-26 PT PT15736015T patent/PT3160948T/pt unknown
- 2015-06-26 HR HRP20190147TT patent/HRP20190147T1/hr unknown
- 2015-06-26 ME MEP-2019-19A patent/ME03316B/me unknown
- 2015-06-26 RS RS20190085A patent/RS58274B1/sr unknown
- 2015-06-26 TR TR2019/00659T patent/TR201900659T4/tr unknown
- 2015-06-26 AU AU2015282450A patent/AU2015282450C1/en active Active
- 2015-06-26 UY UY0001036195A patent/UY36195A/es not_active Application Discontinuation
- 2015-06-26 DK DK15736015.7T patent/DK3160948T3/en active
- 2015-06-29 US US14/753,239 patent/US9394291B2/en active Active
- 2015-06-29 TW TW104120998A patent/TWI677498B/zh active
- 2015-06-30 AR ARP150102098A patent/AR101036A1/es active IP Right Grant
-
2019
- 2019-01-24 CY CY20191100097T patent/CY1121596T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA43382A (fr) | Modulateurs des récepteurs des chimiokines | |
| SI3160948T1 (sl) | Amidi benzoksazinona, kot modulatorji receptorja mineralokortikoida | |
| EP3390437C0 (en) | TARGETED DISRUPTION OF THE MHC CELL RECEPTOR | |
| CL2016002055A1 (es) | Uso de compuestos 3-isoxazolidinonas como herbicidas selectivos | |
| CL2016002129A1 (es) | Compuestos de azolina | |
| IL248991B (en) | Substituted dihydroisoquinolinone compounds | |
| DK3490986T3 (da) | Piperidin-cxcr7-receptormodulatorer | |
| DK3560954T3 (da) | Modificeret j-kæde | |
| DK3151960T3 (da) | Ikke-pgm-ammoniakslipkatalysator | |
| CL2016001742A1 (es) | Anticuerpos anti-baff novedosos | |
| DK3113873T3 (da) | Katalysatorindretning | |
| EP3226841C0 (en) | ANTICANCER COMPOSITIONS | |
| HUE043290T2 (hu) | Adagoló kapszula | |
| LT3319963T (lt) | Pakeistieji 4-azaindolai ir jų, kaip glun2b receptoriaus moduliatorių, panaudojimas | |
| LT3572405T (lt) | Benzoimidazol-1,2-ilo amidai, kaip kv7 kanalų aktyvatoriai | |
| EP3140625C0 (en) | MIXING DEVICE | |
| EP3395436A4 (en) | MICRO REACTOR | |
| CL2016002165A1 (es) | Compuestos de aminocarbonilcarbamato | |
| LT3183242T (lt) | Pakeistieji bicikliniai junginiai | |
| IL247140B (en) | Pyrazines modulators of gpr6 | |
| DK3145916T3 (da) | Imidazolderivater som formylpeptidreceptormodulatorer | |
| EP3490401C0 (en) | SECURITY FIXTURE | |
| DE112015005590A5 (de) | Dosierpumpe | |
| DK3190088T3 (da) | Fremgangsmåde til syntese af ammoniak | |
| HUE036206T2 (hu) | N,N-bisz-2-merkaptoetil-izoftálamid új alkalmazása |